CytoNiche, HeXun Biosciences & Level Biotechnology Establish Strategic Partnership for Large-Scale MSC Manufacturing

Date : 2026-09-24

Publisher : Cytoniche | Marketing

CytoNiche’s 3D FloTrix™ platform enables automated MSC manufacturing at tens-of-billions scale through a new tripartite partnership in Taiwan.

CytoNiche Biotech, a global leader in 3D bioprocessing and automated cell manufacturing solutions, today announced a milestone tripartite strategic collaboration with Taiwan-based regenerative medicine CDMO HeXun Biosciences Co., Ltd. and Level Biotechnology Inc.

Under this cooperation, HeXun Biosciences has successfully implemented CytoNiche’s flagship biodegradable microcarrier platform and the 3D FloTrix™ vivaSPIN series bioreactor system to establish a fully automated, commercial-scale mesenchymal stem cell (MSC) manufacturing pipeline. The integrated platform has been officially deployed for large-scale MSC production and client services, achieving an outstanding single-batch capacity of tens of billions (1010) of cells.

Pioneering Next-Generation 3D Cell Biomanufacturing

As an innovator originating from Peking University’s research ecosystem with headquarters and operations in China and Singapore, CytoNiche provides complete, end-to-end solutions spanning reagents, consumables, automated equipment, and process development.

At the heart of this deployment is CytoNiche’s proprietary 3D TableTrix™ microcarrier platform, which features:

High Porosity & Controllable Particle Size: Enables adherent cells to thrive in suspension culture while retaining stemness and phenotypic stability.
Gentle Dissolution & High Yield: Allows seamless, enzyme-free degradation during harvesting for maximum cell recovery without compromising viability.
Full-Chain Integration: Offers seamless scalability from upstream expansion, harvest, and fluid exchange to automated aseptic filling.

CytoNiche’s cell manufacturing technology has already demonstrated commercial-grade reliability in major markets, notably backing the bioprocess for Amimestrocel Injection, China’s first commercially approved hMSC drug.

Furthermore, CytoNiche’s core microcarrier platforms hold multiple U.S. FDA Drug Master File (DMF) and Master File (MF) registrations, alongside NMPA CDE filings, ensuring global regulatory compliance and seamless international market entry for partner CDMOs and therapeutics developers.

A Tripartite Synergy for Regional and Global Expansion

The strategic alignment leverages the unique strengths of each partner to construct an integrated Asia-Pacific regenerative medicine supply chain:

CytoNiche Biotech: Serves as the core technology developer and innovator, providing state-of-the-art 3D bioprocessing equipment, biodegradable microcarriers, and global market connectivity.
HeXun Biosciences: Operates as a premier CDMO and key manufacturing hub, utilizing CytoNiche’s platform within its GMP-compliant smart cell manufacturing facility to serve global client pipelines.
Level Biotechnology Inc.: Acts as CytoNiche's trusted regional agent and technical bridge in Taiwan, overseeing local system integration, supply chain maintenance, and after-sales equipment and consumable services.

Beyond technology transfer, CytoNiche will actively connect HeXun to its extensive industrial networks across China, Singapore, and Southeast Asia, introducing international partners and potential customers to expand the reach of this joint manufacturing ecosystem.

Leadership Commentary

"We are thrilled that, through our valued partnership with Level Biotechnology, CytoNiche’s advanced 3D bioprocessing technology has landed in Taiwan to empower HeXun Biosciences. Together, we are building a robust international bridge for standardized, high-yield cell biomanufacturing."

— Dr. Yan Xiaojun, Co-Founder & Chief Technology Officer of CytoNiche Biotech

"CytoNiche’s microcarrier platform can multiply production efficiency while ensuring cell quality. This is a key breakthrough for us in the field of MSC manufacturing."

— Chen Songyuan, Vice President of HeXun Biosciences Co., Ltd.

"Level Biotechnology is dedicated to driving genuine industrial chain cooperation. We are delighted to facilitate this tripartite collaboration, upgrading regional process capabilities while setting the stage for turnkey biomanufacturing exports."

— Chen Binghui, Senior Product Manager of Level Biotechnology Inc.

Looking Ahead

CytoNiche will continue working closely with HeXun Biosciences and Level Biotechnology to extend the 3D FloTrix™ platform into additional cell modalities, exosome production, and versatile bioreactor application scenarios, delivering GMP-compliant, modular cell manufacturing solutions to the global regenerative medicine market.

None

CytoNiche’s 3D RecomTrix™ Recombinant Collagen Microcarriers Complete U.S. FDA DMF and MF Filings